Help researchers crack the code! Sign up for Epidemiology of Young Lung Cancer. More research + more knowledge leads to new treatments and a cure.
Displaying archives for Bradley Newton, Author at ALCMI - Addario Lung Cancer Medical Institute:
Genomics of Young Lung Cancer ALCMI Study Published
ALCMI’s GOYLC study has been published in JTO Clinical and Research Reports. Click here to read the full text article.
First Patient Enrolled in Biodesix and Addario Lung Cancer Medical Institute Study Aiming to Predict Patient Survival Using a Blood-based Biomarker
Study will evaluate the use of a blood-based biomarker to predict outcomes in high PD-L1 expressing non-small cell lung cancer patients treated with immune checkpoint inhibitors plus or minus chemotherapy
Epidemiology of Young Lung Cancer
This study seeks to help better understand why an increasing number of young people are developing lung cancer. Specifically, we are looking to study the environmental and childhood exposures, and other risk factors for lung cancer in persons under age 40.
SPACEWALK – A Study for Patients with ALK Drug Resistance
This study seeks to better understand this kind of cancer and to develop new future lung cancer treatments. Specifically, we are looking for genetic changes in the ALK gene that could help to understand why a cancer has developed drug resistance.
Remote Participation Enables Patients with ALK-Positive Lung Cancer from Across the Country to Participate in New Study of Treatment Resistance
The Addario Lung Cancer Medical Institute (ALCMI), a patient-founded not-for-profit global research consortium, and researchers from the Dana-Farber Cancer Institute are launching a novel nationwide […]
Patients Launch New Study to Shed Light on EGFR-Positive Lung Cancers
The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology and EGFR Resisters today announced the launch of a new study to create a novel bank of patient derived xenograft (PDX) models to help researchers better understand why patients living with epidermal growth factor receptor (EGFR) positive lung cancer develop resistance to treatment over time, or […]
Addario Lung Cancer Medical Institute Collaborates with Washington University on ctDNA Analysis in Early Stage Lung Cancer Study
InVision® ctDNA liquid biopsy platform being explored to help inform the management of patients following surgery of curative intent. The Addario Lung Cancer Medical Institute (ALCMI)… Read More
Motivated Patients with ROS1 Cancer Initiate Global Research Study
Global collaboration among data scientists, engineers, developers, coders, radiologists and physicians to end the world’s deadliest cancer. The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology (NASDAQ: CSBR) and the ROS1ders announce the commencement of a global study to gain a deeper understanding of ROS1-positive cancer. The study is developing patient-derived xenografts (PDX) models for […]
The Fight of Our Lives: Confronting the Unmet Need in Lung Cancer
Medical advancements, over the past year, have been game changing for lung cancer patients. In 1971, President Richard Nixon declared war on cancer, and now, we finally have a war on lung cancer. In 2015, the FDA approved 7 new treatments for lung cancer patients, and 5 of these approvals came over a 2-month period.